Loading clinical trials...
Loading clinical trials...
A Combined Rising Single-Dose (RSD) and Rising Multiple-Dose (RMD) Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of KX2-391 in Patients With Advanced Malignancies That Are Refractory to Conventional Therapies
Conditions
Interventions
Src kinase inhibitor KX2-391
immunoenzyme technique
+1 more
Locations
1
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
October 1, 2007
Primary Completion Date
August 1, 2008
Completion Date
March 1, 2009
Last Updated
March 2, 2011
NCT05139017
NCT00001350
NCT05529069
NCT06263491
NCT06337318
NCT07388563
Lead Sponsor
Roswell Park Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions